Showing results (341-350 of 434) with videos related to
Sort By:
Pageof 44
European Journal of Nuclear Medicine and Molecular Imaging|September 27, 2008
Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CTAshley M Groves, Gordon C Wishart, Manu Shastry, et al.Technology in Cancer Research & Treatment|January 11, 2015
Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy PlanningShankar Siva, Thomas Devereux, David L Ball, et al.JCO Precision Oncology|January 7, 2022
Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management ModelEryn Dow, Alison Freimund, Kortnye Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinibLinda Mileshkin, Rodney J Hicks, Brett G M Hughes, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 22, 2018
What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?Guy-Anne Turgeon, Amir Iravani, Tim Akhurst, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2020
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor ModelCarleen Cullinane, Charmaine M Jeffery, Peter D Roselt, et al.Journal of Medicinal Chemistry|April 7, 2021
A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive CancerAlicia Corlett, Marc-Antoine Sani, Jessica Van Zuylekom, et al.The Journal of Clinical Endocrinology and Metabolism|January 23, 2016
Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and ParagangliomaAidan Flynn, Trisha Dwight, Jessica Harris, et al.Journal of Medicinal Chemistry|August 21, 2009
Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearanceIvan Greguric, Stephen R Taylor, Delphine Denoyer, et al.Pageof 44